These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 19454589)

  • 1. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype.
    Rizzo M; Berneis K; Hersberger M; Pepe I; Di Fede G; Rini GB; Spinas GA; Carmina E
    Hum Reprod; 2009 Sep; 24(9):2286-92. PubMed ID: 19454589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
    Doi SA; Abbas JM; Parkinson L; Chakraborty J; Akanji AO
    Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid and lipoprotein profile in women with polycystic ovary syndrome.
    Macut D; Panidis D; Glisić B; Spanos N; Petakov M; Bjekić J; Stanojlović O; Rousso D; Kourtis A; Bozić I; Damjanović S
    Can J Physiol Pharmacol; 2008 Apr; 86(4):199-204. PubMed ID: 18418429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
    Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
    Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?
    Rizzo M; Berneis K; Carmina E; Rini GB
    Am J Obstet Gynecol; 2008 Jan; 198(1):28.e1-5. PubMed ID: 18166299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
    Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
    Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of ovulatory cycles with aging in women with polycystic ovary syndrome (PCOS) alters the trajectory of cardiovascular and metabolic risk factors.
    Carmina E; Campagna AM; Lobo RA
    Hum Reprod; 2013 Aug; 28(8):2245-52. PubMed ID: 23595974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls.
    Cho LW; Kilpatrick ES; Keevil BG; Jayagopal V; Coady AM; Rigby AS; Atkin SL
    Horm Metab Res; 2011 Feb; 43(2):141-5. PubMed ID: 21234853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low estradiol-to-testosterone ratio is associated with oligo-anovulatory cycles and atherogenic lipidic pattern in women with polycystic ovary syndrome.
    Amato MC; Verghi M; Nucera M; Galluzzo A; Giordano C
    Gynecol Endocrinol; 2011 Aug; 27(8):579-86. PubMed ID: 20608809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.
    Rocha MP; Marcondes JA; Barcellos CR; Hayashida SA; Curi DD; da Fonseca ÂM; Bagnoli VR; Baracat EC
    Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
    Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
    Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.
    Maitra A; Pingle RR; Menon PS; Naik V; Gokral JS; Meherji PK
    Int J Fertil Womens Med; 2001; 46(5):271-7. PubMed ID: 11720200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS.
    Zhang J; Fan P; Liu H; Bai H; Wang Y; Zhang F
    Hum Reprod; 2012 Aug; 27(8):2484-93. PubMed ID: 22674204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome.
    Hernández-Mijares A; Bañuls C; Gómez-Balaguer M; Bergoglio M; Víctor VM; Rocha M
    Eur J Clin Invest; 2013 Jun; 43(6):549-56. PubMed ID: 23528141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of endothelial dysfunction, lipid metabolism in women with polycystic ovary syndrome: relationship of paraoxonase 1 activity, malondialdehyde levels, low-density lipoprotein subfractions, and endothelial dysfunction.
    Bayram F; Kocer D; Ozsan M; Muhtaroglu S
    Gynecol Endocrinol; 2012 Jul; 28(7):497-501. PubMed ID: 22703625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.